Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Revive Therapeutics Ltd. (OTC: RVVTF).

Full DD Report for RVVTF

You must become a subscriber to view this report.


Recent News from (OTC: RVVTF)

Revive Therapeutics provides update on its cannabis-based pharmaceuticals initiatives
Revive Therapeutics ( OTCQB:RVVTF ) provides an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for unmet medical needs and rare diseases. More news on: Revive Therapeutics Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 05 2018 08:08
Revive Therapeutics Provides Update on its Cannabis-based Pharmaceuticals Initiatives
TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) ("Revive" or the “Company”) , a specialty cannabis company focused on the research, development and commercialization of novel cannabis-based products, is pleased...
Source: GlobeNewswire
Date: September, 05 2018 07:00
Revive Therapeutics provides corporate update
Revive Therapeutics ( OTCQB:RVVTF ) provides a corporate update on its product strategy and business development activities. More news on: Revive Therapeutics Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 28 2018 08:18
AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech or the “Company” ) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that it has signed an exclusive distribution and license agreement ...
Source: GlobeNewswire
Date: August, 27 2018 09:00
Revive Therapeutics Applies To FDA For Orphan Drug Designation of Cannabidiol For Treatment Of Liver Transplantation
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”) , a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Adm...
Source: GlobeNewswire
Date: August, 22 2018 07:00
5 of Today's Biggest Marijuana Stock Gainers - Wednesday, June 27th
Out of over 200+ marijuana stocks , here are 5 of the biggest marijuana stock winners in trading on Wednesday, June 27th including AXIM Biotechnologies, Inc. (OTC:AXIM) and more... Amfil Technologies Inc. (OTC:AMFE) Shares of Amfil Technologies Inc. rose 11.63% on higher than average trad...
Source: Daily Marijuana Observer
Date: June, 27 2018 18:07
Revive Therapeutics Announces FDA Grants Orphan Drug Designation
TORONTO, June 27, 2018 -- / D.M.O. Newswire / -- Revive Therapeutics Ltd. ( TSXV:RVV ) ( OTC:RVVTF ) ( FSE:31R ) ("Revive" or the "Company"), a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Drug ...
Source: Daily Marijuana Observer
Date: June, 27 2018 11:13
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis
TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company") , a company focused on the research, development and commercialization of novel cannabinoid-based therapies, today announced that the U.S. Food and Dr...
Source: GlobeNewswire
Date: June, 27 2018 07:00
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive
Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF...
Source: SeekingAlpha
Date: June, 15 2018 10:00
Revive Therapeutics teams up with WeedMD to develop medical cannabis products
Revive Therapeutics ( OTCQB:RVVTF ) inks medical cannabis R&D supply and collaboration agreements with WeedMD ( OTCPK:WDDMF ) aimed at developing treatments for nonalcoholic steatohepatitis (NASH) and autoimmune hepatitis (AIH). More news on: Revive Therapeutics Ltd., WeedMD Inc, Hea...
Source: SeekingAlpha
Date: June, 13 2018 07:47

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.075N/AN/A0
2018-12-130.0750.0750.0750.0752,500
2018-12-120.0680.07510.07510.06739,000
2018-12-110.0780.06820.079240.068225,300
2018-12-10N/A0.078N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1231,00039,00079.4872Short
2018-12-0711,90014,70080.9524Short
2018-12-04256,0250.4149Cover
2018-12-033,50021,00016.6667Cover
2018-11-291,5001,500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RVVTF.


About Revive Therapeutics Ltd. (OTC: RVVTF)

Logo for Revive Therapeutics Ltd. (OTC: RVVTF)

Revive Therapeutics Ltd. TSX VENTURE:RVV OTCQB:RVVTF is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs by identifying and investigating potential drugs and cannabinoids that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities or prodrugs. Additional information on Revive is available at www.ReviveThera.com.

 

Contact Information

 

 

Current Management

  • Craig Leon / CEO
  • Fabio Andrea Chianelli / President
  • Carmelo Marrelli / CFO
  • Beverly James Incled / VP, R amp D
  • Craig Leon / Chairman
  • Fabio Andrea Chianelli /

Current Share Structure

  • Market Cap: $9,840,965 - 03/15/2018
  • Issue and Outstanding: 53,893,567 - 04/12/2017

 


Recent Filings from (OTC: RVVTF)

OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: February, 21 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: February, 13 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: February, 13 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: January, 09 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: January, 09 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: January, 09 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: January, 09 2018
Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: January, 09 2018
Interim Financial Report - Interim Financial Report
Filing Type: Interim Financial Report - Interim Financial ReportFiling Source: OTC Markets
Filing Date: January, 09 2018
Supplemental Information - Supplemental Information
Filing Type: Supplemental Information - Supplemental InformationFiling Source: OTC Markets
Filing Date: January, 09 2018

 

 


Daily Technical Chart for (OTC: RVVTF)

Daily Technical Chart for (OTC: RVVTF)


Stay tuned for daily updates and more on (OTC: RVVTF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RVVTF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RVVTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RVVTF and does not buy, sell, or trade any shares of RVVTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/